CAMBRIDGE, Mass., May 14, 2024
/PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq:
AKBA), a biopharmaceutical company with the purpose to better the
lives of people impacted by kidney disease, today announced that
John Butler, Chief Executive
Officer, will participate in a fireside chat at the 2nd
Annual HCW Bioconnect Investor Conference on Monday, May 20th, 2024 at 3:00 p.m. ET.
The 2nd Annual HCW Bioconnect Investor Conference
will take place in New York, NY on
May 20, 2024.
A webcast of the presentation can be accessed through the
"Investors" section of Akebia's website at https://ir.akebia.com
for 30 days following the conference.
About Akebia Therapeutics
Akebia Therapeutics,
Inc. is a fully integrated biopharmaceutical company with the
purpose to better the lives of people impacted by kidney
disease. Akebia was founded in 2007 and is
headquartered in Cambridge,
Massachusetts. For more information, please visit our
website at www.akebia.com, which does not form a part
of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-2nd-annual-hcw-bioconnect-investor-conference-302144820.html
SOURCE Akebia Therapeutics, Inc.